Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Contraindications to pegylated-interferon or ribavirin in HCV patients in the USA

A study published ahead of print in Alimentary Pharmacology & Therapeutics reports on contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic Hepatitis C.

News image

Chronic Hepatitis C treatment with pegylated-interferon ribavirin is often limited by preexisting medical, psychiatric and psychosocial contraindications.

However, limited data exist in general patient populations.

Dr Talal and colleagues from New York, USA evaluated the percentage of chronic Hepatitis C-infected patients in the general US population who may have contraindications to pegylated-interferon.

The General Electric Centricity dataset was used to screen the US population between 2004 and 2009 for chronic Hepatitis C infection and contraindications to  pegylated-interferon.

Chronic Hepatitis C diagnosis and contraindications were identified using ICD-9-CM codes or laboratory values.

The researchers reported that only patients with an encounter 180 days prior to chronic Hepatitis C diagnosis were included.

The team of doctors determined frequencies and percentages for absolute and relative contraindications to pegylated-interferon and/or ribavirin, and calculated proportions and rates per 1000 person-months.

17% had at least one contraindication to pegylated-interferon
Alimentary Pharmacology & Therapeutics

A total of 15,561,021 patients were screened, and 45,690 who were chronic Hepatitis C-positive were evaluated.

The research team observed that those with contraindications were significantly younger, female, White, not currently married and receiving Medicare or Medicaid coverage.

The team observed that 17% had at least one contraindication to pegylated-interferon, including bipolar disorder, anemia, pregnancy, and neutropenia.

Dr Talal's team concludes, "Approximately, 17% of chronic Hepatitis C-infected patients in the general US population had at least one contraindication to pegylated-interferon."

"Most contraindications were relative and potentially modifiable."

"Clinical assessment of contraindications as relative and/or modifiable should be considered and used to determine if patients could benefit from current pegylated-interferon–containing triple therapy or future pegylated-interferon– or ribavirin-free regimens."

Aliment Pharmacol Ther 2013: 37(4): 473–481
24 January 2013

Go to top of page Email this page Email this page to a colleague

 30 June 2015

Advanced search
 30 June 2015 
NSAIDs and hearburn symptoms
 30 June 2015 
Glucocorticoids and peptic ulcer bleeding
 30 June 2015 
Split-dose preparations vs day-before bowel cleansing regimens
 29 June 2015 
Rescue therapy in ulcerative colitis
 29 June 2015 
Prevention of pancreatitis after ERCP
 29 June 2015 
Advances in autoimmune pancreatitis
 26 June 2015 

Gene polymorphism in alcoholic liver disease

 26 June 2015 
Dietary fibre–microbiota interactions
 26 June 2015 
Gastritis in celiac disease
 25 June 2015 
Persistent organ failure in acute cholangitis patients
 25 June 2015 
Vitamin D level and primary biliary cirrhosis
 25 June 2015 
Fecal microbiota in pediatric IBD
 24 June 2015 
Environmental risk in IBD
 24 June 2015 
Fatigue scales for IBD
 24 June 2015 
Mucosal healing tests in ulcerative colitis
 23 June 2015 
Marker associated with endoscopic lesion in Crohn's
 23 June 2015 
Body composition in children with IBD
 23 June 2015 
Medical vs nurse endoscopists
 22 June 2015 
Gene polymorphism associated with increased liver enzymes
 22 June 2015 
Treatment of uncomplicated acute appendicitis
 22 June 2015 
Solid organ cancers after liver transplant
 19 June 2015 
Causes of death in HBV
 19 June 2015 
Lifetime benefits of increased adenoma detection rates
 19 June 2015 
Acid-suppressive therapy before anti-reflux surgery
 18 June 2015 
Endoscopic activity in symptomatic IBD patients
 18 June 2015 
Regimens for H. pylori eradication
 18 June 2015 
Risk for dyspepsia
 17 June 2015 
Non-invasive markers of advanced liver fibrosis
 17 June 2015 
Patients’ and clinicians’ perception of pouch dysfunction
 17 June 2015 
NAFLD risk in celiac disease
 16 June 2015 
Esophageal food bolus impaction
 16 June 2015 
Evaluating lymph node metastasis for rectal cancer
 16 June 2015 
Risk score for hepatocellular carcinoma screening
 15 June 2015 
Low-cost colonoscopy training
 15 June 2015 
Determining dysbiosis in IBS or IBD
 15 June 2015 
Light alcohol consumption and NAFLD
 12 June 2015 
Smoking and disease course in IBD
 12 June 2015 
Hep D in a Hep B endemic area
 12 June 2015 
Patient-orientated internet information in ulcerative colitis
 11 June 2015 
Physical inactivity and NAFLD
 11 June 2015 
Esophageal stricture after endoscopic resection
 11 June 2015 
Guideline based screening strategies for hepatitis
 10 June 2015 
Cost-effectiveness of HCV treatment in liver disease
 10 June 2015 
Abdominoperineal excision for low rectal cancer
 10 June 2015 
Pediatric chronic Hep C
 09 June 2015 
Bile acid malabsorption in IBS
 09 June 2015 
Racial differences in celiac disease
 09 June 2015 
Conversion from laparoscopic to open colorectal cancer resection
 08 June 2015 
Short sleep duration and NAFLD
 08 June 2015 
Heritability in inflammatory bowel disease
 08 June 2015 
Eosinophilic esophagitis
 05 June 2015 
In-hospital mortality in patients with lower GI bleeding
 05 June 2015 
Scoring system for microscopic colitis
 05 June 2015 
H. pylori and myocardial infarction
 04 June 2015 
Mucosal healing in celiac disease and pregnancy
 04 June 2015 
Gastrointestinal microbiomes in Crohn's
 04 June 2015 
Dyspepsia in the community:
 03 June 2015 
Predicting disease activity in IBD
 03 June 2015 
Outcomes with discontinuation of therapy in Crohn's
 03 June 2015 
Biopsies in eosinophilic esophagitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us